In collaboration with Comprehensive Blood & Cancer Center, Cancer Check Labs is the first to demonstrate the ability to detect and produce images of whole circulating tumor cells (CTCs) in stage 0 and stage 1 breast cancer patients.
Detailed in a new white paper, Cancer Check Labs has successfully produced whole images of CTCs from the blood of several breast cancer patients, which comprised tangible cellular tissue that can be placed on a glass slide for visual inspection by a board-certified pathologist. Upon examination, a board-certified pathology report that conforms with established standard of care protocols is issued to the customers. Further, because the research has shown CTCs to be detected as early as Stage 0, Cancer Check arguably provides the earliest cancer detection test available.
Among the many implications of CTC detection is the potential for providing invaluable information to ascertain their site and tissue of origin when radiology or other screening methods are unable. The use of immunochemical and immunofluorescent staining techniques to isolated CTCs like those shown in Cancer Check Labs‘ samples can swiftly narrow down the most likely site(s) of origin, e.g. lung, thyroid, breast, or colon, based on the characteristic pattern of positive and negative antibody staining that has been described in the literature for various types of cancers.
Unlike other currently available early cancer detection blood tests which produce liquid biopsies with ctDNA-based partial detection and carry a high percentage of false positives, Cancer Check Labs has the ability to detect 200+ known types and subtypes of solid tumors with just a blood draw through the identification of whole circulating tumor cells.
In essence, the Company is producing a whole body tissue biopsy from a blood sample; a process which doesn’t rely on complicated machine learning algorithms or artificial intelligence and which easily fits into established medical protocols.
SOURCE Cancer Check Labs LLC
Entdecke mehr von LabNews
Melde dich für ein Abonnement an, um die neuesten Beiträge per E-Mail zu erhalten.
